Europe - Euronext Milan - BIT:1BAX - US0718131099 - Common Stock
The current stock price of 1BAX.MI is 30.905 EUR.
ChartMill assigns a technical rating of 2 / 10 to 1BAX.MI.
ChartMill assigns a fundamental rating of 3 / 10 to 1BAX.MI. 1BAX.MI may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months 1BAX.MI reported a non-GAAP Earnings per Share(EPS) of 2.45. The EPS increased by 0.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.52% | ||
| ROE | -9.32% | ||
| Debt/Equity | 1.79 |
22 analysts have analysed 1BAX.MI and the average price target is 35.44 EUR. This implies a price increase of 14.66% is expected in the next year compared to the current price of 30.905.
For the next year, analysts expect an EPS growth of -7.17% and a revenue growth 6.13% for 1BAX.MI
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 2M6.DE | MEDTRONIC PLC | 17.21 | 107.02B | ||
| 1SHL.MI | SIEMENS HEALTHINEERS AG | 19.62 | 52.88B | ||
| SHL.DE | SIEMENS HEALTHINEERS AG | 18.68 | 50.37B | ||
| 1PHIA.MI | KONINKLIJKE PHILIPS NV | 17.36 | 24.74B | ||
| PHI1.DE | KONINKLIJKE PHILIPS NV | 16.51 | 23.53B | ||
| PHIA.AS | KONINKLIJKE PHILIPS NV | 16.55 | 23.58B | ||
| BIM.PA | BIOMERIEUX | 27.05 | 12.36B | ||
| OBCK.DE | OTTOBOCK SE & CO KGAA | 141.91 | 4.27B | ||
| DIA.MI | DIASORIN SPA | 22.82 | 4.23B | ||
| 1AFX.MI | CARL ZEISS MEDITEC AG - BR | 23.24 | 3.55B | ||
| AFX.DE | CARL ZEISS MEDITEC AG - BR | 23.3 | 3.36B | ||
| DRW3.DE | DRAEGERWERK AG - PREF | 14.25 | 1.72B |
Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. The company is headquartered in Deerfield, Illinois and currently employs 38,000 full-time employees. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. The company provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.
BAXTER INTERNATIONAL INC
1 Baxter Parkway,
Deerfield ILLINOIS US
Employees: 60000
Phone: 18442945418
Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. The company is headquartered in Deerfield, Illinois and currently employs 38,000 full-time employees. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. The company provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.
The current stock price of 1BAX.MI is 30.905 EUR. The price increased by 0.57% in the last trading session.
BAXTER INTERNATIONAL INC (1BAX.MI) has a dividend yield of 2.17%. The yearly dividend amount is currently 1.05.
1BAX.MI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
22 analysts have analysed 1BAX.MI and the average price target is 35.44 EUR. This implies a price increase of 14.66% is expected in the next year compared to the current price of 30.905.
The Revenue of BAXTER INTERNATIONAL INC (1BAX.MI) is expected to grow by 6.13% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
BAXTER INTERNATIONAL INC (1BAX.MI) has a market capitalization of 15.85B EUR. This makes 1BAX.MI a Large Cap stock.